COMMUNIQUÉS West-GlobeNewswire

Tyme Announces Presentation of Clinical Data on SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
04/01/2018
Mack Roach, M.D., FASCO , University of California, San Francisco, to present data from ongoing Phase II clinical trial NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq: TYME ), a clinical- [...]
HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance
04/01/2018
Fourth quarter 2017 revenue expected to be between $6.9 and $7.2 million Full year 2017 revenue expected to be between $13.8 and $14.1 million Initial full year 2018 revenue guidance of $20.0 to $25.0 million TUCSON, [...]
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
04/01/2018
- Final protocol confirmed for pivotal Phase 3 clinical trial in pro-opiomelanocortin (POMC) deficiency obesity - - Setmelanotide granted Orphan Drug Designation for treatment of leptin receptor (LEPR) deficiency [...]
Paul Stead Joins Adaptimmune as Vice President of Business Development
04/01/2018
PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR [...]
Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
04/01/2018
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX ), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of papers [...]
Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer
04/01/2018
GEN-1 to Enter the Clinic in Mid-2018 Following a Phase IB Trial Which Demonstrated 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated Compelling [...]
Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
04/01/2018
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers announced today that Ivan [...]
IntelGenx To Present at Biotech Showcase(TM) 2018
04/01/2018
SAINT-LAURENT, Quebec, Jan. 04, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") today announced that its President and Chief Executive Officer, Dr. Horst Zerbe, is [...]
Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute
04/01/2018
Agreement related to study of rigosertib in pediatric RASopathies Clinical trial in pediatric patients to be conducted by the National Cancer Institute RASopathies are orphan diseases believed to be caused by molecular [...]
Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference
04/01/2018
BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX ) announced today that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual [...]
OraSure Technologies Announces Management Succession Plan
04/01/2018
BETHLEHEM, Pa., Jan. 04, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ), a leader in point of care diagnostic tests and specimen collection devices, today announced a succession plan for its [...]
Orion to renew operating model of its laboratories
04/01/2018
ORION CORPORATION PRESS RELEASE 4 JANUARY 2018 at 11.15 Orion to renew operating model of its laboratories Orion improves the competitiveness of its laboratory operations by renewing their operating model in Finland. As [...]
BioNTech Secures USD 270 Million in Series A Financing
04/01/2018
MAINZ, Germany, Jan. 04, 2018 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced it has completed a USD 270 million Series A round [...]
OSE Immunotherapeutics to present at Biotech Showcase™ 2018 Conference
04/01/2018
During JP Morgan Healthcare Conference San Francisco, January 8-10, 2018 NANTES, France, Jan. 04, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announced that Dominique [...]
ASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
04/01/2018
SINGAPORE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]
Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
04/01/2018
Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%[1] Promacta is [...]
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT JANUARY 1, 2018
04/01/2018
NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT January 1, 2018 Marseille, France, January 4, 2018, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of [...]
NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER JANVIER 2018
04/01/2018
nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 1 er janvier 2018 Marseille, le 4 janvier 2018, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]
ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
04/01/2018
GHENT, Belgium, 4 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific [...]

Pages